ATC codes:
L01DB01
EMLc
Indication
Kaposi sarcoma of unspecified primary site
ICD11 code:
2C27.Z
INN
Doxorubicin
Medicine type
Chemical agent
List type
Complementary
Formulations
Parenteral > General injections > IV:
2 mg per mL in 10 mL vial (hydrochloride) ;
2 mg per mL in 25 mL vial (hydrochloride)
EML status history
First added in 2023
(TRS
1049)
Sex
All
Age
Also recommended for children
Therapeutic alternatives
The recommendation is for this specific medicine
Patent information
Main patents have expired but secondary patents might remain active in some jurisdictions. For more
information on specific patents and license status for developing countries visit www.MedsPal.org
Read more
about patents.
Tags
Wikipedia
Summary of evidence and Expert Committee recommendations
The Expert Committee recommended the inclusion of pegylated liposomal doxorubicin on the complementary list of the EML and EMLc for the treatment of Kaposi sarcoma. The Committee noted evidence that pegylated liposomal doxorubicin is associated with similar or improved survival benefits and reduced harms in comparison to non-liposomal doxorubicin and other routinely used chemotherapies, and pegylated doxorubicin is a preferred therapeutic alternative to paclitaxel in children as the experience with paclitaxel in this setting is still rather limited